Core Insights - Kontoor Brands is raising its full year outlook due to stronger revenue and earnings growth, enhanced cash generation, and benefits from Project Jeanius, which aims to transform its global operating model and optimize its supply chain [1] Revenue Outlook - Revenue is now expected to be at the high end of the previous outlook range of $3.09 to $3.12 billion, indicating a growth of approximately 19 to 20 percent compared to the prior year [1] Operational Strategy - The forecast includes a 30 percent reciprocal tariff on China and a 20 percent reciprocal tariff on other sourcing countries, except Mexico, and the company plans to offset tariff impacts through price increases, supply chain optimization, and inventory management over a 12-to-18-month period [3] Pricing Strategy - Pricing adjustments have been implemented as part of a comprehensive strategy to mitigate tariff impacts, with changes effective mid-June for direct-to-consumer and in July for wholesale [4] Revenue Performance - Q3 2025 revenue reached $853 million, reflecting a 27 percent increase compared to the prior year [4] - Wrangler brand revenue increased by 2 percent to $471 million, contributing to broad-based growth and market share gains [5] Market Share Gains - Wrangler's U.S. revenue grew by 1 percent, driven by an 11 percent increase in direct-to-consumer sales, while U.S. wholesale remained flat due to shipment timing shifts [6] - Wrangler's international revenue increased by 6 percent, supported by a 5 percent rise in wholesale and a 12 percent increase in direct-to-consumer [6] - Q3 marks Wrangler's 14th consecutive quarter of market share gains, with the core men's and women's bottoms business gaining 80 basis points of market share [7]

Financial Performance - The company experienced a 39% year-over-year increase in revenue for 1Q25 [11] - Adjusted EBITDA increased by 84% in 1Q25 compared to 1Q24 [11] - Net income saw a significant increase of 316% in 1Q25 compared to 1Q24 [11] - The sale of 44% of the Sunlight cluster contributed $80 million to revenues and income and $42 million to Adjusted EBITDA in 1Q25 [14] - The company reaffirms its 2025 guidance with revenues and income projected between $490 million and $510 million, and Adjusted EBITDA between $360 million and $380 million [11] Growth and Expansion - The company's revenues and Adjusted EBITDA have a Compound Annual Growth Rate (CAGR) nearing 40% since 2018 [15] - The company plans to build 4.7 FGW of capacity in 2025 [37] - The company is targeting $1.4 billion in revenues and income by year-end 2027 [35] - The company is entering the data center sector, leveraging its core capabilities [38] Tariff Mitigation and Financial Strategy - The company has no exposure to tariffs on solar panels for projects reaching COD by the end of 2026 [11] - 80% of the batteries for projects are purchased from Tesla, resulting in lower tariff exposure [11, 24] - The company completed $1.5 billion in financial closings for three U S projects in the past four months [11]

Financial Data and Key Metrics Changes - In Q1 2025, sales grew 4% as reported and 7% in constant currency, reaching $662 million, at the high end of guidance [10][25][28] - Earnings per share (EPS) were $2.25 on a non-GAAP basis, reflecting low single-digit growth, and $2.03 on a GAAP basis [11][29] - Gross margin was 58.2%, and adjusted operating margin was 25.5% [29][36] Business Line Data and Key Metrics Changes - Instrument sales grew 11%, driven by mid-teens growth in liquid chromatography and mass spectrometry, particularly in pharma and industrial markets [11][27] - Recurring revenue increased mid-single digits, consistent with expectations for a quarter with two fewer days [11][28] - The chemistry consumables business saw MaxPeak Premier columns grow more than 30% [15] Market Data and Key Metrics Changes - Pharma sales grew 8%, industrial sales grew 6%, and academic and government sales grew 3% [25][26] - In China, sales grew 5%, with double-digit growth in industrial and academic/government applications [11][25] - India delivered revenue growth close to 20% in constant currency, driven by strong demand from generics manufacturers and CDMOs [18][61] Company Strategy and Development Direction - The company is focused on operational excellence, innovation, and maintaining close customer relationships to navigate a dynamic macro environment [8][21] - The strategy includes launching differentiated new products and investing in capabilities to enhance competitive positioning [8][21] - The company raised its full-year constant currency sales growth guidance to 5% to 7% due to better-than-expected Q1 performance [22][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 objectives despite challenges from newly announced tariffs [9][38] - The company expects high single-digit earnings growth for the year, supported by strong sales volume and favorable foreign exchange movements [10][21] - Management noted that the pharma industry remains attractive, with strong innovation and customer spending [52][72] Other Important Information - The company established a cross-functional task force to assess tariff exposure and implement mitigation plans, limiting the net impact of tariffs to $10 million on adjusted operating margin for 2025 [24][36] - The company is actively evaluating M&A opportunities to enhance long-term shareholder value and may resume share repurchase programs in 2025 [31][99] Q&A Session Summary Question: Can you discuss the replacement cycle dynamics in pharma biotech? - Management noted strong double-digit growth in instruments, particularly in large pharma, with the replacement cycle well underway [45][46] Question: Have you seen any change in behavior related to tariffs from pharma customers? - Management indicated no significant change in behavior, with strong momentum continuing through the quarter [49][50] Question: What are your expectations for pricing this year? - Management expects 200 basis points of like-for-like pricing gains, with additional surcharges related to tariffs contributing another 50 basis points [56][57] Question: How do you view the growth in India? - Management expressed confidence in the sustainability of growth in India, driven by strong demand from generics manufacturers [60][61] Question: What is the impact of tariffs on your supply chain? - Management detailed actions taken to mitigate tariff impacts, including inventory adjustments and selective surcharges [64][66] Question: What are your expectations for China for the balance of the year? - Management anticipates low single-digit growth in China for the remainder of the year, despite a strong start [76][77] Question: What is the latest on the academic and government segment? - Management indicated that this segment is small, accounting for about 3% of total revenue, and has seen a significant decline forecasted for the rest of the year [86][89]

Financial Data and Key Metrics Changes - The company reported robust organic sales growth of 10.1% in Q1 2025, with adjusted EPS of $2.84, reflecting a 13.6% increase compared to Q1 2024 [5][6][16] - The adjusted gross margin improved to 65.5%, up 190 basis points year-over-year, while the adjusted operating margin was 22.9%, an increase of 100 basis points [24][25] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 10.7%, with U.S. growth at 11.4% and international growth at 8.2% [16][20] - Orthopedics saw organic sales growth of 9.3%, with U.S. knee business growing 8.3% and hip business growing 7.6% [20][21] - Trauma and Extremities businesses grew 15.2% organically, driven by strong performance in core trauma and upper extremities [22][58] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.7%, while international organic sales growth was 8.5%, with notable strength in Australia, New Zealand, Japan, and Europe [15][20] - The company anticipates continued strength in procedural demand, particularly in robotic-assisted surgery [9][10] Company Strategy and Development Direction - The company completed the acquisition of Inari Medical, with integration going well and expected to contribute positively to the vascular division [6][12][51] - The company is focused on maintaining double-digit organic sales growth, with guidance for 2025 set at 8.5% to 9.5% [6][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, citing strong demand and no major red flags in the operating environment [41][42] - The company is taking measures to mitigate the estimated $200 million impact from tariffs through pricing strategies and operational efficiencies [27][34] Other Important Information - The company is recognized for the fifteenth consecutive year on Great Place to Work's list of 100 Best Companies to Work For [7] - The company expects to launch Mako Spine in the second half of 2025 and Mako Shoulder in Q1 2026 [10][12] Q&A Session Summary Question: How is the company absorbing the $200 million tariff impact? - The company plans to offset the tariff impact through strong sales momentum, pricing strategies, and optimizing the supply chain [31][34] Question: What is the outlook for the orthopedics market? - The orthopedics market remains healthy, with strong demand and expectations for growth above the market average [36][37] Question: How is the launch of LifePack 35 progressing? - The launch is going well, with strong order pipelines and positive market reception [68][70] Question: What are the expectations for capital expenditures in 2026? - Early conversations suggest continued strength in capital demand, particularly tied to procedural needs [100][101] Question: How is the integration of Inari going? - The integration is progressing well, with strong early performance and alignment with Stryker's culture [51][52]